Drug intelligence / Profile preview

TNB-384B

Development stage: Preclinical
Lead developer: Amgen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Intratumoral

Overview

TNB-384B is a bispecific monoclonal antibody developed by Teneobio. It is designed to target B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells, thereby redirecting the body's own T-cells to kill tumor cells. Unlike its counterpart TNB-383B, TNB-384B features a high-activating alphaCD3 moiety, which results in more pronounced T-cell activation and cytokine release while demonstrating similar efficacy in killing multiple myeloma cells in preclinical studies.

Targets

BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on TNB-384B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNB-384B.

Explore the full profile